Liquid biopsy is transforming precision oncology by delivering faster, more comprehensive insights. In this session, NeoGenomics will share clinical and technical perspectives on the PanTracer LBx assay, a new blood-based comprehensive genomic profiling test. Dr. Sugganth Pillei will present a patient case illustrating RET fusion detection and therapy impact, discussing PanTracer LBx capabilities and workflow integration with QCI Interpret One to deliver expert interpretation and oncologist-ready reports. Early results from 340 patients highlight detection rates, actionable findings, concordance and scalability for clinical use. Dr. Ryan Bender will discuss technical innovations, including AMP library preparation, soft-clipped read analysis, semiconductor sequencing and VAF monitoring.
